Obesity and obesity-related metabolic diseases represent a growing socioeconomic
problem throughout the world. Great emphasis has been put on establishing treatments for�…

The neuropeptide Y (NPY)/peptide YY (PYY) system has been implicated in the physiology
of obesity for several decades. More recently, Batterham et al. 2002 ignited enormous�…

Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully�…

New appetite‐regulating antiobesity treatments such as semaglutide and agents under
investigation such as tirzepatide show promise in achieving weight loss of 15% or more�…

Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic�…

Arising from: RL Batterham et al. Nature 418, 650–654 (2002); Batterham et al. reply
Batterham et al. report that the gut peptide hormone PYY3–36 decreases food intake and�…

Aim: Previous studies with the novel once daily glucagon‐like peptide‐1 (GLP‐1) analogue
liraglutide and the GLP‐1 receptor agonist exenatide have revealed profound�…

Metabolic effects of the glucagon-like peptide-1 analog liraglutide and the dipeptidyl
peptidase-IV inhibitor vildagliptin were compared in rats made obese by supplementary�…

The development and pharmacology of a new potent growth hormone (GH) secretagogue,
ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)�…

A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of
amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue�…